Abstract
Clinicians have historically used family history and other risk prediction algorithms to guide patient care and preventive treatment such as statin therapeutics for coronary artery disease. As polygenic scores move towards clinical use, we have begun to consider the interplay of these scores with other predictors for optimal second generation risk prediction. Here, we assess the use of family history and polygenic scores as independent predictors of coronary artery disease and type 2 diabetes. We highlight considerations for use of family history as a predictor of these two diseases after evaluating their effectiveness in the Trøndelag Health Study and the UK Biobank. From these, we advocate for collection of high resolution family history variables in biobanks for future prediction models.
Competing Interest Statement
C.J.W.'s spouse works for Regeneron Pharmaceuticals. J.B.N. is employed by Regeneron Pharmaceuticals, Inc.
Funding Statement
Funding for this study was provided by the National Institutes of Health to C.J.W. (R01 HL127564, R35 HL135824) and M.B. (U01 DK062370, R01 HG009976). B.N.W. was funded by NSF Graduate Research Fellowship (DGE 1256260) and NIH Training Program in Genomic Science (T32 HG000040). N.J.D. was funded by a Foundation for Anesthesia Education and Research (FAER) Mentored Research Training Grant. W.Z. was supported by the National Human Genome Research Institute of the National Institutes of Health under award number T32HG010464.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The HUNT study has previously received human subjects approval at the University of Michigan and the Norwegian University for Science and Technology (NTNU). The Institutional Review Boards of the University of Michigan Medical School (IRBMED) provided ethical approval under HUM00126227. The Regionale komiteer for medisinsk og helsefaglig forskningsetikk (REK) provided ethical approval with REK-midt approving study 2015/1209 and REK-sø r-øst approving study 2016/885. All study participants provided written informed consent and are consented for dbGaP deposition. HUNT subjects were recruited from a region of Northern Norway, and the total number of participants in the HUNT Biobank is 78,951 individuals. We have obtained human subjects approval for sequencing studies on HUNT subjects both from NTNU and University of Michigan. Sharing of de-identified materials is covered by existing informed consents and IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code is publicly available on GitHub (https://github.com/bnwolford/FHiGR_score) and summary statistics are made available in the manuscript. Individual level data is not available for participant privacy.
